These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36730747)

  • 1. Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents.
    Ma B; Zhao W; Fan H; Yun Y; Qi S; An H; Yang F
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):27-33. PubMed ID: 36730747
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
    Hendset M; Hermann M; Lunde H; Refsum H; Molden E
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin serum concentrations during aripiprazole treatment in youth.
    Safer DJ; Calarge CA; Safer AM
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):282-9. PubMed ID: 23647135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients.
    Dorado P; de Andrés F; Naranjo ME; Peñas-Lledó EM; González I; González AP; de la Rubia A; Llerena A
    Drug Metabol Drug Interact; 2012; 27(3):165-70. PubMed ID: 23089607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia.
    Jiang P; Sun X; Ren J; Liu H; Lin Z; Liu J; Fang X; Zhang C
    Gen Psychiatr; 2021; 34(2):e100423. PubMed ID: 33851072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia.
    Tasaki M; Yasui-Furukori N; Kubo K; Yokoyama S; Shinozaki M; Sugawara N; Inoue Y; Shimoda K
    Ther Drug Monit; 2021 Aug; 43(4):589-592. PubMed ID: 33235024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting.
    Sogawa R; Shimomura Y; Minami C; Maruo J; Kunitake Y; Mizoguchi Y; Kawashima T; Monji A; Hara H
    J Clin Psychopharmacol; 2016 Aug; 36(4):385-7. PubMed ID: 27281387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy.
    Sugai T; Suzuki Y; Yamazaki M; Sugawara N; Yasui-Furukori N; Shimoda K; Mori T; Ozeki Y; Matsuda H; Okamoto K; Sagae T; Someya T
    J Clin Psychopharmacol; 2020; 40(1):14-17. PubMed ID: 31834097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
    Bachmann CJ; Rieger-Gies A; Heinzel-Gutenbrunner M; Hiemke C; Remschmidt H; Theisen FM
    Ther Drug Monit; 2008 Aug; 30(4):462-6. PubMed ID: 18641558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Nemoto K; Mihara K; Nakamura A; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2012 Apr; 34(2):188-92. PubMed ID: 22377745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: A retrospective clinical study.
    Liu X; Sun X; Li L; Zeng K; Li Y; Gao Y; Ma J
    Front Psychiatry; 2023; 14():1124691. PubMed ID: 36816406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia].
    Baymeeva NV; Miroshnichenko II; Platova AI; Tikhonov DV; Kaleda VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):98-103. PubMed ID: 35175709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
    Molden E; Lunde H; Lunder N; Refsum H
    Ther Drug Monit; 2006 Dec; 28(6):744-9. PubMed ID: 17164689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes.
    Xin Y; Gao L; Tuo Y; Nie G; Mei Y; Chen C; Wang J; Li S; Sun D; Qian Q; Fu Y; Wang Y; Liu Z
    Front Pharmacol; 2022; 13():1048498. PubMed ID: 36532742
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
    Nagai G; Mihara K; Nakamura A; Nemoto K; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2017 Feb; 39(1):62-65. PubMed ID: 27861318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
    Peuskens J; Pani L; Detraux J; De Hert M
    CNS Drugs; 2014 May; 28(5):421-53. PubMed ID: 24677189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Nagai G; Kagawa S; Nemoto K; Ohta I; Arakaki H; Uno T; Kondo T
    Ther Drug Monit; 2011 Feb; 33(1):21-4. PubMed ID: 21157400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.